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Summary In syngeneic mice, the H5V polyoma middle-T oncogene-transformed endothelioma cell line induces Kaposi's sarcoma-like
cavernous haemangiomas that regress transiently, probably because of an anti-tumour immune response, but eventually grow progressively
and kill the host. To evaluate the generation of tumour-specific cytotoxic T lymphocytes (CTLs), spleen cells of tumour-bearing mice were
restimulated with irradiated H5V cells in mixed leucocyte-tumour cell cultures. Tumour-specific CTLs were demonstrable only when low
numbers of H5V stimulator cells were used (<1 H5V cell per 50 splenocytes). We found that H5V cells secrete immunosuppressive mediators
because CTL generation was blocked when H5V cells culture supernatants were added to allogeneic mixed leucocyte cultures. As numerous
tumour-derived immunosuppressive mediators may interfere with interleukin 12 (IL-12) production, we tested whether IL-12 treatment of the
tumour-bearing mice would augment their immune response and thus suppress tumour growth. Indeed, IL-12 inhibited tumour growth and
prevented mortality, but did not increase anti-H5V CTL generation either in vitro or in vivo. Moreover, the anti-tumour activity in IL-12-treated
mice was abrogated by anti-interferon (IFN)-y monoclonal antibody (MAb) co-administration. These results strongly suggest that the anti-
tumour effect of IL-12 is principally mediated by IFN-y release that in turn blocks H5V cell proliferation and induces the release of factors that
suppress angiogenesis.
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The H5V endothelioma cell line was originally derived by trans-
forming mouse embryonic heart cells with a retroviral construct
expressing the polyoma middle-T oncogene (Garlanda et al,
1994). When injected into syngeneic C57BL/6 mice, this cell line
causes cavernous haemangiomas similar to Kaposi's sarcoma.
Additional similarities between the two tumours are found at the
level ofcell-surface markerexpression, cytokine secretion profiles
and 'spindle cell' morphology limited to some areas of the
endotheliomas (Garlanda et al, 1994; Sciacca et al, 1994).
Previous data have suggested that the H5V tumour was
immunogenic because the haemangiomas transiently regressed in
immunocompetent mice, but grew progressively and killed
immunodeficient or immunosuppressed hosts. Moreover, mice
that regressed their tumours were resistant to a second challenge
with a higher dose of H5V cells (Garlanda et al, 1994). The
C57BL/6 mouse strain was found to be highly responsive to the
polyoma virus as it was resistant to a dose of virus that caused
tumours in three other inbred mouse strains tested concomitantly.
Further immunogenetic analysis showed that this resistance is
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associated with the H-2b MHC haplotype (Freund et al, 1992). As
anti-tumour cytotoxic T-lymphocyte (CTL) activity may be the
basis ofan effective immunity to solid tumours ofviral origin, our
primary aim was to demonstrate the presence of H5V-specific
CTLs in the tumour-bearing mice (Chieco-Bianchi et al, 1988).
During the course of our studies, we observed that H5V cells
secrete soluble immunosuppressive mediators. PGE2 is the main
prostaglandin produced by normal heart microvascular endothelial
cells, and has often been implicated in tumour-induced immuno-
suppression (Smith, 1986; Sulitzeanu, 1993); therefore, we inves-
tigated whether H5V cells also produce this prostaglandin. Indeed,
the immunosuppressive effect of the tumour may limit the devel-
opment of an effective CTL response in vivo, thus facilitating
tumour growth. We also evaluated whether treatment with inter-
leukin 12 (IL-12), a cytokine whose secretion can be impaired by
products secreted from tumour cells, and which was recently
found to have potent anti-tumour activity against H5V cells
(Vecchi et al, unpublished), could enhance the generation of anti-
tumour CTL and bring about a complete tumour elimination
(Gately, 1993). To test this possibility, tumour-injected animals
were treated with different doses of IL-12, and then tumour
growth, anti-tumour CTL activity and survival of the treated and
control animals were compared. Moreover, as IL-12 induces inter-
feron (IFN)-yproduction in vivo (Gately et al, 1994), the contribu-
tion ofthis cytokine to the in vivo effect ofIL-12 was also studied
by treating tumour-injected mice with anti-interferon (IFN)-y
monoclonal antibody (MAb).
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MATERIALS AND METHODS
Mice and in vivo tumour growth experiments
C57BL/6 and BALB/C mice were purchased from Charles River
(Charles River, Como, Italy). Procedures involving animals and
their care were in conformity with institutional guidelines that
comply with national and international laws and policies (EEC
Council Directive 86/609, OJ L 358, 1, 12 December 1987; NIH
Guide for the Care and Use of Laboratory Animals, NIH
Publication No. 85-23, 1985). Female C57BL/6 mice (8-12 weeks
old) were injected with trypsinized H5V cells subcutaneously
(s.c.) in the left flank. Some tumour-bearing mice were injected
intraperitoneally (i.p.) with a water-soluble salt of indomethacin
(Lyometacen, Chiesi Pharmaceuticals, Parma, Italy; 2 mg kg-' for
20 days). In a further series of experiments, groups of recipients
were injected with 106 H5V cells and treated with different doses
of recombinant murine IL-12 prepared in
phosphate-buffered saline (PBS) containing 1% normal C57BL/6
mouse serum. Some ofthe recipients were treated with anti-IFN-y
MAb as well (clone AN18, 0.3 mg ascites per mouse on day 0 i.v.,
on day 1 and 2 i.p., then 0.2 mg per mouse twice a week i.p. for 3
additional weeks). The IL-12 was a gift from Stan Wolf, Genetics
Institute, Cambridge, MA, USA. Mice were checked several times
daily for survival and premoribund animals were killed by ethyl-
ether overdose.
Preparation of cell suspensions and flow
cytofluorometric analysis
Mice were killed by ether overdose. Single-cell spleen cell suspen-
sions were prepared in Dulbecco's modified Eagle medium
(DMEM) using a nylon mesh. The viability ofthe cell suspensions
was checked by eosin exclusion tests, and was always higher than
85%. Immunofluorescent labelling and flow cytofluorometric
analysis were performed as described previously (Jainossy et al,
1993), using a Coulter Elite flow cytofluorimeter (Coulter
Electronics, Hialeah, CA, USA). Phycoerytrin (R-PE)-labelled rat
anti-mouse CD8 MAb (clone 53-6.7) was purchased from
Pharmingen (San Diego, CA, USA).
Cell cultures
All cell cultures were maintained in complete DMEM [DMEM
supplemented with L-glutamine, Hepes, 2-mercaptoethanol, peni-
cillin, streptomycin and 10% heat-inactivated fetal calf serum
(Flow, Irwine, UK)]. In vitro passages of the H5V cell line were
performed by detaching the adherent tumour cells with 0.25%
trypsin solution containing 2 mm EDTA (Gibco, Paisley, UK).
H5V-specific CTLs were generated by restimulating spleen cells
in mixed leucocyte-tumourcell cultures (MLTCs). Responder spleen
cells from tumour-bearing or normal C57BL/6 mice (2.5 x 107) and
different numbers ofgamma-irradiated (60 Gy) H5V stimulator cells
were cultured in 15 ml ofcomplete DMEM in 25-cm2 tissue culture
flasks (Falcon, Los Angeles, CA, USA). In some experiments, IL-12
was added (0.1-10 ng ml-1) when the cultures were set up. On day 5,
CTL activity was measured in a 5mCr-release assay.
To test the soluble immunosuppressive factors produced by the
H5V cells, supematants of high cell density tumour cell cultures
(> 3 x 105 cells ml-') were added to allogeneic mixed leucocyte
cultures (MLC), which consisted of 2.5 x 107 C57BL/6 spleen
cells stimulated with 2.5 x 107 irradiated (20 Gy) BALB/C spleen
cells (C57BL/6-BALB/C MLC).
PGE2 content of the cell culture supematants was determined
with a commercial ELISA kit (Amersham, Little Chalfont, UK).
51Cr-release assay
Tumour-specific CTL activity was tested using H5V cells as
specific targets and MBL-2 murine leukaemia virus (MuLV)-
induced C57BL/6 lymphoma cells as non-specific targets; in the
case of MLC, LSTRA MuLV-induced BALB/C lymphoma cells
served as specific targets. H5V cells were collected by trypsiniza-
tion; our preliminary experiments showed that this treatment did
not interfere with the killing of the tumour targets by CTLs. One
million target cells were labelled with 100 pCi of 51Cr (sodium
chromate, NEN, Boston, MA, USA) in a volume of0.1 ml for 1 h
at 37°C. The 4-h 5'Cr-release assay was performed in 96-well U-
bottom microtitre plates (Bibby Steriline, Stone Staffs, UK) using
2000 (H5V) or 5000 (LSTRA or MBL-2) 5tCr-labelled target cells
and different numbers of effector cells in a volume of 0.2 ml. All
samples were plated in triplicate. The plates were then centrifuged,
0.1-ml aliquots ofthe supematants were collected and c.p.m. were
counted with a Packard Cobra auto-gamma counter (Packard
Instrument Company, Meriden, CT, USA). Spontaneous 51Cr
release was calculated by incubating the target cells with medium
only, while maximal lysis was measured after treatment with
Triton X-100 detergent. Cytotoxicity was expressed as the
percentage of specific lysis, calculated as 100 x (experimental -
spontaneous release)/(maximal - spontaneous release).
Statistical analysis
Statistical analysis was performed using the GraphPad InStat
computerprogram (GraphPad Software, San Diego, CA, USA) and
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Figure 1 Dose-dependent tumour growth. C57BUI6 mice were injected s.c.
in the left flank with different doses of H5V cells and followed for tumour
growth (15-24 mice per dose). After s.c. inoculation, tumour nodules grew
rapidly and then started to regress 7 days after inoculation. Around day 20,
most recipients were found to be tumour-negative by palpation (tumour
diameter <2 mm). The subcutaneous tumours then reappeared, metastases
developed, and from day 60 the animals started to die
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Figure 3 Immunosuppressive activity of H5V cell culture supernatants.
Allogeneic MLC were set up using 2.5 x 107 irradiated BALB/c stimulator
spleen cells and the same number of C57BU6 respondercells, in the
presence or absence of 2% supematant from 6-day-old confluent cultures of
either H5V or SC-1 cells. After 5 days, allospecific CTL activity was
determined. One LU50 was defined as the number of effector cells causing
specific lysis of 50% of 5000 LSTRA (BALB/c) lymphoma target cells. Data
points represent mean ± s.d. of CTL activity in MLTC of three individual mice.
Shown is a representative example of three independent experiments that
gave similar results
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Figure 2 Generation of H5V-specific CTL activity in MLTC. Spleen cells
(2.5 x 107) were restimulated with 2.5 x 105 irradiated H5V cells. After 5
days, CTL activity was measured in 4-h 5'Cr-release assays using H5V
(specific) and MBL-2 (non-specific) targets. Shown are representative data
from two tumour-bearing (Ti and T2) and one naive (N) mouse in one
experiment. Three independent experiments were performed with similar
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RESULTS
Growth of H5V tumours in syngeneic mice
B6 mice were injected s.c. in the left flank with 2 x 105, 106 or
5 x 106 H5V cells. All mice developed subcutaneous primary
tumours whose diameter was related to the cell dose injected (data
not shown). As previously reported, the H5V-induced tumours
regressed transitorily at around day 20, when most recipients were
found to be tumour-negative by palpation, i.e. tumour diameter
was less than 2 mm (Fig. 1). In the animals autopsied at this time
point, no cavernous haemangiomas were present, and only small
non-vascular remnants ofthe tumours were found (not shown). In
the majority of the animals injected with the higher cell doses,
vascular tumours reappeared and disseminated to the visceral
mesentery, the ovary, the liver, and, albeit rarely, distant subcuta-
neous sites. From day 60, the animals started to die and the cause
of death was usually massive bleeding due to rupture of intra-
abdominal cavernous haemangiomas. In subsequent experiments,
we used the intermediate tumour dose (106 cells), which caused
tumour regrowth and metastases in most ofthe injected mice.
Figure 4 Immunosuppressive activity of H5V cell culture supernatants
collected at different time points after in vitro culture. The supematants from
2-, 4- or 6-day cultures of H5V cells were added at the final concentration of
5% to C57BU6-BALB/c MLC, set up as described in the legend of Figure 3.
On day 5, LU5dMLC were determined (LU50 is the number of effector cells
causing 50% specific lysis of 5000 target cells), and CTL activity was
calculated as the percentage of the CTL activity found in control MLC. Total
LU50 in control MLC without H5V supernatants was 819 ± 104/MLC (n = 3)
Detection of anti-H5V CTL activity in the tumour-
bearing mice
To evaluate CTL generation against H5V tumours, mice were
injected with 106 H5V cells, killed on day 10, and MLTCs were set
up by mixing spleen cells with irradiated H5V stimulator cells;
non-injected mice were analysed in parallel. Surprisingly, the
generation of specific CTL activity was demonstrable only if low
numbers of H5V stimulator cells were used in the MLTC (Fig. 2).
Indeed, maximum cytotoxicity was detected at very low stimulator
to responder ratios (1:100-1:1000). When a stimulator to
responder cell ratio greater than 1:50 was used, no CTL activity
was detected. Control mice did not exhibit appreciable CTL





0Cancer Research Campaign 1998IL-12 treatmentofhaemangiosarcomas 659
e60 nIL1 O 60 - Per cent tumour-free mice on day 120 10 n IL-12
E m, 0 50 100
40 - 1 ,ug IL-12I
n 40 100 ng IL-12 vehicle
20 - 10 ng IL-12
Vehici
0
0 30 60 90 120
Days after tumour inoculation
Figure 5 Prevention of tumour-induced mortality by high-dose IL-12
treatment. Groups of C57BU6 mice were injected with 106 H5V cells and
treated with a daily i.p. dose of 10 ng, 100 ng or 1 9g IL-12 on days 0-4 and
7-11. Control mice received injections of PBS containing 1% mouse serum
('vehicle') alone. Mice were checked for survival every day. After a transient
regression, the subcutaneous tumours regrew and metastases developed in
all control mice. The inset shows the percentage of disease-free mice 120
days after tumour inoculation as determined by inspection for palpable
tumour nodules
activity. The overall cell recovery was usually in the same range in
the MLTC ofboth H5V tumour-bearing and naive mice. However,
in the former, the percentage of CD8+ cells was elevated, and
CD8+ blasts were also detected (data not shown). Peak CTL
activity was found around day 10; it then decreased but remained
detectable even 3 months after the injection in animals bearing
multiple tumours (data not shown).
To investigate whether the low number ofH5V cells required to
induce CTL generation was due to their release ofimmunosuppres-
sive factors, different amounts of H5V cell culture supematants
were added to C57BL/6-BALB/C allogeneic MLC, and cell
recovery and CTL generation were evaluated. The H5V cell culture
supematants inhibited responder cell proliferation and CTL genera-
tion in a dose-dependent fashion, and this suppressive effect was
detectable at supernatant concentrations as low as 2% (Fig. 3).
Supernatants of overgrown cell cultures of the non-malignant SI
fibroblast cell line were also tested, and found to be devoid of
immunosuppressive effects. The immunosuppressive activity of
different H5V culture supernatants varied and was more pronounced
when the in vitro H5V culture time was increased (Fig. 4).
To investigate whether the H5V haemangioma cells secreted
PGE2, a factor that was shown to be responsible for immunosup-
pressive effects, the presence ofPGE2 in H5V cells culture super-
natants was evaluated. We observed thatH5V cells produced PGE2
in variable quantities; in some cases, the PGE2 concentration
reached 1 ng ml-1 (about 3 ng per 106 cells). However, the suppres-
sive activity of different H5V supematants did not correlate
directly with their PGE2 content. The addition of 1 gM of the
cyclooxygenase inhibitor indomethacin to the H5V cultures
completely eliminated PGE2 production, and reduced but did
not eliminate the immunosuppressive effect. Moreover, daily
indomethacin treatment (2 mg kg-' i.p.) of the tumour-bearing
mice in order to block prostaglandin synthesis did not significantly
change recipient survival nor influence the anti-tumour CTL
activity (data not shown).
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Figure 6 H5V-specific CTL activity in untreated and IL-12-treated tumour-
bearing mice. Groups of recipients were killed on day 10 (A) or day 25 (B).
Spleen cells were restimulated in MLTC, and CTL activity was measured at
day 5 using H5V targets. Data points represent mean ± s.d. of values of 3-6
(day 10) or 3-12 (day 25) individual mice. No significant difference was found
between the controls and the IL-12-treated groups at different time points
and E/T ratios (two-tailed Mann-Whitney statistics, P> 0.05) 0, vehicle; 0,
10 ng IL-12; A, 100 ng IL-12; V, 1 9g IL-12
IL-12 blocks tumour growth and decreases tumour-
induced mortality
IL-12 is the key regulator ofcytotoxic cell generation and has been
shown to be required to induce the rejection of experimental
tumours (Trinchieri, 1995; Fallarino et al, 1996); however, various
tumour-derived or tumour-elicited immunosuppressive factors,
including IL-10, transforming growth factor (TGF)-P, or PGE2,
may block its production (Katamura et al, 1995; Trinchieri, 1995;
van der Pouw Kraan et al, 1995). In a recent series ofexperiments,
we found that IL-12 has anti-tumour activity in the H5V system in
vivo (Vecchi et al, unpublished). Thus, we evaluated whether treat-
ment of tumour-bearing mice with recombinant IL-12 could
increase the anti-tumour immune response. Mice injected with 106
H5V cells were treated daily with different doses of IL-12 (from
10 ng to 1 gg i.p.) from the time of tumour cell inoculation to
day 4, and from day 7 to day 11. The administration of 10 ng day-'
IL-12 did not substantially suppress tumour growth, whereas
higher doses significantly decreased the maximal diameter of
primary tumours; the strongest inhibition was achieved when the
highest cytokine dose was used (not shown). After a transient
regression, the tumours regrew in all untreated recipients, and 13 of
18 mice died at the end of the 120-day observation period. In the
case of mice treated with the lowest IL-12 dose, 9 out of 18
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Figure 7 IL-12 added in vitro to anti-H5V MLTC does not influence CTL
generation. Spleen cells (2.5 x 107) from B6 mice injected with 106 H5V cells
(n = 4) were restimulated with 2.5 x 105 irradiated H5V cells in the presence
or absence of IL-12. CTL activity was determined on day 5 using H5V targets,
and mean specific lysis + s.d. was plotted. 0, control; El, 1 ng ml-' IL-12;
A, 10 ng ml-1 IL-12
survived to day 120 but only three were tumor-free. One animal in
a group of 18 treated with 100 ng IL-12 died within 120 days, and
10 of the 17 survivors were tumour-free. All nine animals treated
with 1 gg IL-12 were living at day 120, and only two had palpable
tumours (Fig. 5). The differences between the ratios ofsurvivors in
the control and the two high-dose IL-12 groups were significant
(Fisher's exact test, P < 0.001), as were the differences between the
survival times (two-tailed Mann-Whitney statistics, P < 0.001).
Elimination of tumours by IL-12 treatment is not
accompanied by an increase in cellular immune
reactivity
To check anti-tumour cellular immune reactivity, groups ofIL-12-
treated and control mice were killed on days 10 and 25; spleen cell
suspensions were prepared, MLTCs were set up, and H5V-specific
CTL activity was measured after 5 days in culture.
In the MLTC of tumour-bearing control mice that did not
receive IL-12 treatment a strong H5V-specific CTL activity was
detected on day 10, which decreased slightly by day 25 (stimulator
to responder ratio, 1:100). However, at both time points and with
all three IL-12 doses, the CTL activity of the IL-12-treated mice
was not significantly different from the control values (two-tailed
Mann-Whitney statistics, P > 0.05; Fig. 6).
On day 25, the natural killer (NK) activity of freshly isolated
spleen cells was also evaluated using YAC-1 target cells. The
highest NK activity was detected in the naive controls, whereas
lower values were detected in the untreated tumour-bearing mice
and in mice receiving IL-12 (data not shown).
To further evaluate thepossible effectofIL-12 on anti-H5V CTL
generation, in another group of experiments different doses of
IL-12 (0.1 to 10 ng ml-') were added in vitro to MLTCs of non-
treated tumour-injected mice. Using our standardculture conditions
(stimulator to responder ratio, 1:100), a strong CTL activity was
generated in the cultures ofpooled spleen cells of tumour-injected
mice and was notfurtherincreasedby the addition ofIL-12 (Fig. 7).
Days after tumour inoculation
Figure 8 The anti-tumour activity of IL-12 is abrogated byanti-IFN-y Mab
treatment. C57BU6 mice were injected with 106 H5V cells s.c., and then
treated with IL-12 (1 ,ug per mouse, 5 days a week for 4 weeks) orvehicle;
some of the recipients were also treated with anti-IFN-yantibody (AN18,
0.3 mg per mouse on day 0 iv, on day 1 and 2 ip, then 0.2 mg per mouse
twice a week i.p for 3 additional weeks)
In vivo treatment with anti-IFN-y MAb abrogates the
anti-tumour effect of IL-12
To evaluate the role ofIL-12-induced IFN-yproduction in the anti-
tumour effect of IL-12, non-treated or IL-12-treated tumour-
injected mice were inoculated with anti-IFN-,y MAb. In line with
ourprevious observations, IL-12 treatment had apronounced anti-
tumour effect (P < 0.05, comparison of survival times by two-
tailed Mann-Whitney statistics), whereas repeated injections of
anti-IFN-,y antibody shortened the survival of the recipients even
in comparison with control mice. Moreover, anti-IFN-y MAb
treatment abrogated the anti-tumour effect of IL-12. Indeed, the
survival time of mice receiving both IL-12 and anti-IFN-y MAb
treatment was significantly reduced in comparison with mice
receiving IL-12 only (P = 0.0002, two-tailed Mann-Whitney
statistics), and was even shorter than that of untreated control
mice (Fig. 8).
DISCUSSION
CTLs have been shown to play a major role in the regression of
numerous experimental tumours (Chieco-Bianchi et al, 1988). Our
findings provide direct evidence for the generation ofCTL specific
for H5V tumourantigens as well. These data are in accordance with
our earlier results, which demonstrated that in vivo depletion of
CD8+ T cells by treatment with an anti-CD8 MAb promotes the
growth ofH5V tumours, and accelerates the death ofthe recipients
(Garlanda et al, 1994). H5V-specific CTLs were readily detected in
the MLTC of tumour-bearing mice, but only if low stimulator:
responder cell ratios were used, while high numbers of H5V cells
blockedrespondercell proliferation andCTLgeneration. The obser-
vation ofaCTLresponse in the H5V system contrasts withprevious
reports ofunsuccessful attempts to generate tumour-specific CTL in
polyoma tumour-bearing mice (Dalianis, 1990; Ljunggren et al,
1994). Indeed, the immunogenicity of the middle-T antigen was
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only demonstrated after immunization with middle-T peptide frag-
ments, whereas the development of tumour-specific CTL in
polyoma tumour-bearing mice was not directly shown
(Reinholddson-Ljunggren et al, 1992). A cellular immune response
was observed after immunization with irradiated polyoma virus-
transformed embryonic fibroblasts; interestingly, high numbers of
stimulator cells were also found to block the generation of CTL in
this system, although no detailed description of the phenomenon
was provided (Green et al, 1982).
Therelease ofsoluble immunosuppressive factors by H5V cells in
culture provides an explanation for difficulties in demonstrating a
CTLresponse to tumour antigens using high tumour cell numbers as
stimulators. We observed that H5V cells produce PGE2 in relatively
high quantities; this is not surprising, considering the histological
origin ofthe cell line. Kaposi's sarcomatissues have also been found
to contain highlevels ofPGE2, which underlines the similarity ofthe
two malignancies (Ambrus et al, 1992). PGE2 may play more than
onerole inthedevelopment ofH5V tumours. Itsimmunosuppressive
effects might decrease the efficacy of the anti-tumour cellular
immune response; moreover, its angiogenetic properties may
contribute directly to the growth of these highly vascularized
tumours (Sulitzeanu, 1993; Ben-Av et al, 1995). However, the
suppressive activity of different H5V supernatants did not strictly
correlate with their PGE2 content; furthermore, blocking of
prostaglandin synthesis by indomethacin decreased but did not elim-
inate theimmunosuppressive effectofthe supematants. Theseresults
indicate that PGE2 does not represent the only immunosuppressive
mediator produced by the H5V cells, and we are currently searching
forother suppressive factors in the H5V culture supematants.
IL-12 had a strong, dose-dependent anti-tumour activity in the
H5V tumour model as high doses decreased the size ofthe primary
tumours and prevented tumour regrowth and mortality. It was
expected that 1L-12 treatment would augment the immune reactivity
of the tumour-bearing mice, facilitating tumour rejection. However,
thepossibility thatthe invivo IL-12 treatment actedbyincreasing the
anti-tumour cell-mediated immunity, thus counteracting immuno-
suppression, seems unlikely, as the CTL and NK activities of the
cytokine-treated mice were similar to those ofthe untreated controls.
In the H5V model, as well as in other tumour models (Brunda et
al, 1993; Noguchi et al, 1995; Teicher et al, 1996), relatively high
amounts of IL-12 (100 ng-I gig day-') are necessary for effective
tumour elimination, whereas at least 10- to 100-fold lower doses
were found to be optimal for boosting the cellular immune reac-
tivity to tumour-specific peptide antigens and to viral or parasite
antigens (Biron and Gazzinelli, 1995; Hall, 1995; Noguchi et al,
1995). Therefore, in addition to the lack ofan increase in anti-H5V
CTL activity after IL-12 treatment both in vitro and in vivo, the
discrepancy between the IL-12 dose required to cause tumour
regression and boost a cellular immune response in immunization
models also suggests that mechanisms other than the increase in
cell-mediated immunity might be responsible for the IL-12 effect.
The possibility that IL-12 inhibits H5V tumour cell proliferation
directly seems unlikely, as our preliminary experiments showed
that IL-12 does not substantially influence H5V proliferation in
vitro, as measured by thymidine incorporation (data not shown).
Altematively, IL-12 may inhibit tumour cell proliferation by trig-
gering IFN-yproduction by T lymphocytes and NK cells (Gately et
al, 1994; Nastala et al, 1994). Our previous studies indicated that
IFN-y suppresses H5V cell proliferation in vitro as well as tumour
growth in vivo (Dong et al, 1996). In line with these findings, we
observed that anti-IFN-y MAb co-administration abrogated the
anti-tumour effect conferred by IL-12 treatment, thus IFN-y
production is essential for anti-tumour activity ofIL-12.
Moreover, IL-12 was shown to suppress corneal neovasculariza-
tion induced by angiogenic factors, and, like the anti-H5V activity,
this antiangiogenetic effect was also IFN-y-mediated (Voest et al,
1995). The antiangiogenetic effectofIFN-yis probably theresult of
the induction of the chemokine IP-1O, which was shown to
suppress angiogenesis as well as tumour growth in vivo
(Tannenbaum et al, 1996). Interestingly, leucocytes attracted by IP-
10 seem to be indispensable forits anti-tumour effect (Angiolillo et
al, 1995; Mantovani et al, 1997a,b; Luster and Leder, 1993).
Based on our findings, therefore, we advance that the anti-
tumour effect of IL-12 in H5V tumour-bearing mice is mediated
principally by IFN-,y, which not only exerts an inhibitory effect on
H5V cell proliferation but probably also on neoangiogenesis. In
this regard, it should be stressed that H5V tumours are cavernous
haemangiomas consisting of a bulk of recruited host endothelial
cells, and a small percentage of true malignant cells, which are
also endothelial in origin (Garlanda et al, 1994). Therefore, both
the anti-tumour and the antiangiogenetic effects of the IFN-,y
induced after IL-12 treatment may contribute to the prevention or
regression ofthis peculiar tumour. However, at present there lacks
a methodology to separate these effects. The similarities of the
H5V tumour model to Kaposi's sarcoma may open the possibility
ofusing IL-12 to treat Kaposi's sarcoma as well.
ACKNOWLEDGEMENTS
We thank Dr V Bronte and Dr D D'Agostino for critical reading of
the manuscript and V Barbieri for technical assistance. This work
was supportedby theAssociazione ItalianaperlaRicerca sul Cancro
(AIRC), by Grants from the Italian Ministry ofPublic Education, by
AIDS project (No 9403-68) from the Istituto Superiore Sanita to A
Mantovani andby the European Community Project EC-ALA/MED
Countries International Scientific Cooperation. C Vizler and L
Quintieri are supported by fellowships from Associazione Italiana
per la Ricerca sul Cancro. A Rosato is supported by a fellowship
from the Istituto Superiore di Saniti -Progetto AIDS.
REFERENCES
Ambrus JL, Stoll HL, Klein EA, Karakousis CP and Stadler S (1992) Increased
prostaglandin E2 and cAMP phosphodiesterase levels in Kaposi's sarcoma - a
virus against host defense mechanism. Res Com Chem Pathol Pharmacol 78:
249-252
Angiolillo ALC, Sgadari C, Taub DD, Liao F, Farber JM, Maheswari S, Kleinman
H, Reaman GH and Tosato G (1995) Human interferon-inducible protein 10 is
a potent inhibitor ofangiogenesis in vivo. JExp Med 182: 155-162
Ben-Av P, Crofford LJ, Wilder RL and Hla T (1995) Induction ofvascular
endothelial growth factor expression in synovial fibroblasts by prostglandin E
and interleukin-1: a potential machanism for inflammatory angiogenesis. FEBS
Lett372: 83-87
Biron CA and Gazzinelli RT (1995) Effects ofIL-12 on immune responses to
microbial infections: a key mediator in regulating disease outcome. Curr Opin
Immunol 7: 485-496
Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, WolfSF
and Gately MK (1993) Antitumor and antimetastatic activity ofinterleukin-12
against murine tumors. JExp Med 178: 1223-1230
Chieco-Bianchi L, Collavo D and Biasi G (1988) Immunologic unresponsiveness to
murine-leukemia-virus antigens: mechanism and role in tumor development.
Adv Cancer Res 51: 277-306
Dalianis T (1990) Studies on the polyoma virus tumor-specific transplantation
antigen (TSTA). Adv Cancer Res 55: 57-85
c) Cancer Research Campaign 1998 British JournalofCancer(1998) 77(4), 656-662662 C Vizler etal
Dong QG, Graziani A, Garlanda C, Wainstok de Calmanovici R, Arese M, Soldi R,
Vecchi A, Mantovani A and Bussolino F (1996) Anti-tumor activity of
cytokines against opportunistic vascular tumors in mice. IntJ Cancer 65:
700-708
Eallarino F, Uyttenhove C, Boon T and Gajewski T (1996) Endogenous IL-12 is
necessary for rejection ofP815 tumor variants in vivo. J Immunol 156:
1095-1100
Freund R, Dubensky T, Bronson R, Sotnikov A, Carrol L and Benjamin T (1992)
Polyoma tumorigenesis in mice: Evidence for dominant resistance and
dominant susceptibility genes ofthe host. Virology 191: 724-731
Garlanda C, Parravicini C, Sironi M, De Rossi M, Wainstok de Calmanovici R,
Carozzi F, Bussolino F, Colotta F, Mantovani A and Vecchi A (1994)
Progressive growth in immunodeficient mice and host cell recruitment by
mouse endothelial cells transformed by polyoma middle-sized T antigen:
Implications for the pathogenesis ofopportunistic vascular tumors. Proc Natl
AcadSci USA 91: 7291-7295
Gately MK (1993) Interleukin-12: A recently discovered cytokine with potential for
enhancing cell-mediated immune responses to tumors. Cancer Invest 11:
500-506
Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE,
Anderson TD, Sarmiento U, Hubbard BR and Murphy M (1994)
Administration of IL-12 to normal mice enhances cytolytic lymphocyte activity
and induces production ofIFN-y in vivo. Int Immunol 6: 157-167
Greene MI, Perry LL, Kinney-Thomas E and Benjamin TL (1982) Specific thymus-
derived (T) cell recognition ofpapova virus-transformed cells. JImmunol 128:
732-736
Hall SS (1995) IL-12 at the crossroads. Science 268: 1432-1434
Janossy T, Baranyi L, Knulst AC, Vizler C, Benner R, Kelenyi G and Vegh P (1993)
Autoimmunity, hyporeactivity to T cell mitogens and lymphoproliferative
disorders following neonatal induction oftransplantation tolerance in mice.
Eur J Immunol 23: 3011-3020
Katamura K, Shintaku N, Yamaguchi Y, Fukui T, Ohshima Y, Mayumi M and
Furusho K (1995) Prostaglandin E2 priming of naive CD4+ T cells inhibits
acquisition ofability to produce IFN-yand 11-12, but not IL-4 and I1-5.
J Immunol 155: 4604-4612
Ljunggren G, Ljunggren H-G and Dalianis T (1994) T cell subsets involved in
immunity against polyoma virus-induced tumors. Virology 198: 714-716
Luster AD and Leder P (1993) IP-10, a -C-X-C- chemokine, elicits a potent thymus-
dependent antitumor response in vivo. J. Exp. Med. 178: 1057-1065
Mantovani A, Bussolino F and Introna M (1997a) Endothelial cell activation by
cytokines: from molecular level to the bed side. Immunol Today 18: 231-240
Mantovani A, Vecchi A, Sozzana S, Sica A and Allavena P (1997b) Tumors as a
paradigm for the in vivo role ofchemokines in leukocyte recruitment. In
Chemokine and Cancer, Rollins B (ed), Humana Press: Totova NJ, USA (in
press).
Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ,
Gately MK, WolfSF, Schreiber RD, Storkus WJ and Lotze MT (1994)
Recombinant IL-12 administration induces tumor regression in association with
IFN-yproduction. J Immunol 153: 1697-1706
Noguchi Y, Richards EC, Chen YT and Old U (1995) Influence of interleukin-12 on
P53 peptide vaccination against established Meth A sarcoma. Proc NatlAcad
Sci USA 94: 2219-2223
Reinholdsson-Ljunggren G, Ramquist T, Ahrlund-Richter L and Dalianis T (1992)
Immunization against polyoma tumors with synthetic peptides derived from the
sequences ofmiddle- and large-T antigens. Int J Cancer 50: 142-146
Sciacca FL, Sturzl M, Bussolino F, Sironi M, Brandstetter H, Zietz C, Zhou D,
Matteucci C, Peri G, Sozzani S, Benelli R, Arese M, Albini A, Colotta F and
Mantovani A (1994) Expression ofadhesion molecules, platelet-activating
factor, and chemokines by Kaposi's sarcoma cells. JImmunol 180: 4816-4825
Smith WL (1986) Prostaglandin biosynthesis and its compartmentation in vascular
smooth muscle and endothelial cells. Annu Rev Physiol 48: 251-262
Sulitzeanu D (1993) Immunosuppressive factors in human cancer. Adv Cancer Res
60: 247-267
Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM and
Hamilton TA (1996) Cytokine and chemokine expression in tumors ofmice
receiving systemic therapy with IL-12. J Immunol 156: 693-659
Teicher BA, Ara G, Manon K and Schaub RG (1996) In vivo studies with
interleukin- 12 alone and in combination with monocyte colony-stimulating
factor and/or fractionated radiation treatment. Int J Cancer 65: 80-84
Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with
immunoregulatory functions that bridge innate resistance and antigen-specific
adaptive immunity. Annu Rev Immunol 13: 251-276
van der Pouw Kraan TCTM, Boeije LCM, Smeenk RJT, Wijdens J and Aarden LA
(1995) Prostaglandin-E2 is a potent inhibitor ofhuman IL-12 production.
J Exp Med 181: 775-779
Voest EE, Kenyon BM, Reilly MSO, Truitt G, Amato RJD and Folkmann J (1995)
Inhibition of angiogenesis in vivo by interleukin 12. JNatl Cancer Inst 87:
581-586
British Journal ofCancer (1998) 77(4), 656-662 0 CancerResearch Campaign 1998